“Revolutionizing Gene Therapy: The Potential of Russian Drug Development”

“We are at the very beginning of the heyday of gene preparations. Many companies, having seen the commercial success of the same Zolgensma, rushed to develop the same technologies. In terms of quality, Russian drugs may well correspond to foreign developments. The manufacturing method is quite logical and simple. Turnkey production can be established on average within a year. There are even Chinese companies from which you can order bioreactors, and entire chains for obtaining and purifying the drug, ready-made production sites on a turnkey basis. By analogy with the production of the Sputnik V coronavirus vaccine, the mass production of which was established very quickly.

Of course, the distribution of Russian gene therapy drugs will increase their availability for all patients, not only in our country, but also abroad. There are more than seven thousand orphan diseases in the world, in general they affect 6-8% of the entire population of the earth, and treatment is available in a very small number of countries and for a very limited number of diseases. Less than 30% of all patients with this disease in the world receive drugs for SMA, for example, due to its very high cost.”